Article

Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profiling

2022-01-05

Abstract excerpt

<title>Abstract</title> <p>Pembrolizumab is approved in many advanced solid tumor types, however predictive biomarkers and the proportion of pembrolizumab-benefiting patients vary. Biomarkers beyond PD-L1 immunohistochemistry, microsatellite instability (MSI) status, and tumor mutation burden (TMB) may improve benefit prediction. Here, leveraging treatment data (time to next treatment [TTNT]) and comprehensive ge...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 191ca7bb-fe89-52aa-bb49-32a3d45bab7f
DOI: 10.21203/rs.3.rs-1225960/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profilingDOI 10.21203/rs.3.rs-1225960/v1Read

Biomarker study of pembrolizumab in patients with advanced rare cancers.Semantic proximity Read

Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.Semantic proximity Read

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesSemantic proximity Read

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity Read

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivitySemantic proximity Read

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.Semantic proximity Read

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.Semantic proximity Read

Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab.Semantic proximity Read

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity Read

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.Semantic proximity Read

The Predictive and Prognostic Value of T- and B-cell Transcriptomic Signatures for Clinical Response to Immune Checkpoint Blockade in Pleural MesotheliomaSemantic proximity Read

A Novel Patient-specific Protein Expression-based Algorithmic Model for Immune Checkpoint Inhibition Therapy Response Prediction in a Pan-cancer CohortSemantic proximity Read